stockrowAclarion, Inc.
ACON Healthcare Health Information Services
Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024.
- Revenue
- +78.5%
- EPS
- +67.9%
- Free cash flow
- −74.2%
Quarter to September 2026, against a year earlier
Follow ACON
Alert me
Aclarion, Inc. (ACON) EV/Sales
As of 6 November 2026, Aclarion, Inc. (ACON) trades at a EV/Sales of −94.9×. Over the past ten years it has ranged from −240× (April 2025) to 245× (June 2023); the current reading is higher than 33% of that period. That is below the Health Information Services industry median of 2.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −123× | — |
| FY2024 | 29.9× | 53.87% |
| FY2023 | 19.5× | (63.86%) |
| FY2022 | 53.8× | 17.01% |
| FY2021 | 46.0× | 0.00% |
| FY2020 | 46.0× | 0.00% |
| FY2019 | 46.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | −73.8× | — |
| Jun 2026 | −107× | — |
| Mar 2026 | −152× | — |
| Dec 2025 | −123× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACON Aclarion, Inc. | −98.0× |
| HLTHQ Cue Health Inc. compare | −1.1× |
| ZCMD Zhongchao Inc. compare | −0.5× |
| WORX SCWorx Corp. compare | −0.3× |
| VSEE VSee Health, Inc. compare | 0.1× |
| HCTI Healthcare Triangle, Inc. compare | 0.4× |
| BFRG Bullfrog AI Holdings Inc. compare | 6.0× |
| MGRX Mangoceuticals, Inc. compare | 9.6× |
| MSPR MSP Recovery, Inc. compare | 27.0× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)